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Depressive Symptoms and Brain Metabolite Alterations   
in Subjects at Ultra-high Risk for Psychosis:   
A Preliminary Study 
 
 
 
ObjectiveaaRecent neuroimaging studies have suggested that brain changes occur in sub-
jects at ultra-high risk (UHR) for psychosis while experiencing prodromal symptoms, among 
which depression may increase the risk of developing a psychotic disorder. The goal of this 
study is to examine brain metabolite levels in the anterior cingulate cortex, the left dorso-
lateral prefrontal cortex and the left thalamus in subjects at UHR for psychosis and to com-
pare brain metabolite levels between the UHR subjects with comorbid major depressive dis-
order and healthy controls. 
MethodsaaProton magnetic resonance spectroscopy was used to examine brain metabo-
lite levels. Twenty UHR subjects and 20 age- and intelligence quotient (IQ)-matched he-
althy controls were included in this study. 
ResultsaaOverall, no significant differences were observed in any metabolite between the 
UHR and healthy control group. However, UHR subjects with major depressive disorder 
showed significantly higher myo-inositol (Ins) levels in the left thalamus, compared to the 
healthy control. 
ConclusionaaOur results demonstrate that increased thalamic Ins level is associated with 
prodromal depressive symptoms. Further longitudinal follow-up studies with larger UHR 
sample sizes are required to investigate the function of Ins concentrations as a biomarker 
of vulnerability to psychosis.   Psychiatry  Invest  2009;6:264-271
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Introduction 
 
Recently, structural brain changes in subjects at ultra-high risk (UHR) for psycho-
sis have been reported in several brain regions, including the hippocampus
1,2 and an-
terior cingulate cortex (ACC).
3 However, the inconsistency of previous findings sug-
gests us that subtle structural changes might occur before the onset of psychosis, which 
are not enough to be detected through the structural magnetic resonance imaging (MRI). 
Therefore, in vivo proton magnetic resonance spectroscopy (1H-MRS) would greatly 
enhance our understanding of potential early brain changes in UHR subjects by as-
sessing several brain chemicals such as N-acetylaspartate (NAA), creatine (Cr), cho-
line (Cho), myo-inositol (Ins), glutamine and glutamate. 
Few MRS studies have examined subjects at UHR for psychosis. Wood et al.
4 re-
ported a significant increase in NAA/Cr and Cho/Cr ratios in the dorsolateral pre-
frontal region of the UHR group. Decreased NAA/Cr and NAA/Cho ratios in the left 
frontal lobe and decreased NAA/Cr ratios in the ACC were also reported in UHR
subjects.
5 Recently, Aydin et al.
6 reported decreased NAA levels and prolonged T2 
relaxation time of tissue water in the genu of the corpus callosum in the UHR cases 
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as well as in the first-episode patients of developing 
schizophrenia. In addition, there was a report that brain 
metabolite such as NAA was correlated with duration of 
prodromal symptoms in the first-episode patients of de-
veloping schizophrenia.
13 
On the other hand, depression is particularly common 
prodromal symptom in schizophrenia
7 and may increase 
the risk of developing a psychotic disorder.
8,9 In several 
MRS studies examining patients with major depressive 
disorder  (MDD), brain metabolite abnormalities were 
reported in several brain regions.
10,11 In addition, reduc-
ed activation of the dorsolateral prefrontal regions was 
observed in subjects at high genetic risk of schizophre-
nia with depressive symptoms.
12 These findings suggest 
us that it is important to consider the influence of depres-
sion on brain metabolites status when examining neuro-
chemical abnormalities in subjects at UHR for psychosis. 
In this study, we primarily examined absolute value 
of brain metabolites in the ACC, the dorsolateral pre-
frontal cortex (DLPFC), and the left thalamus in subjects 
at UHR for psychosis. In addition, we examined differ-
ences in brain metabolites among UHR subjects with co-
morbid MDD, UHR subjects without MDD, and healthy 
subjects and investigated the correlation of brain meta-
bolite levels with duration of prodromal symptoms. We 
used the absolute concentrations of metabolites in this 
study since relative concentrations using total Cr as an 
internal standard might result in false interpretation of 
data if Cr changed under certain conditions.
14 
 
Methods 
 
Subjects 
The subjects enrolled in this study were part of a pro-
spective, longitudinal project investigating individuals 
at high risk for psychosis at the Seoul Youth Clinic. 
The UHR group consisted of 20 subjects. UHR was 
determined based on the Comprehensive Assessment of 
At-Risk Mental States (CAARMS) criteria.
15 Individuals 
were considered as being at UHR if they met the criteria 
for UHR for psychosis and at least one of following: at-
tenuated psychotic symptoms (APS), brief, limited inter-
mittent psychotic symptoms (BLIPS), or trait plus state 
risk factors (T & S RF). Eighteen subjects met the in-
take criteria for APS and three met the T & S RF criteria. 
In addition, one subject met both the APS and T & S RF 
criteria. Eleven subjects in the UHR group (55%) were 
diagnosed with comorbid MDD, eight with anxiety dis-
order, and one with bipolar disorder, as determined via 
the Structured Clinical Interview for DSM-IV Axis I 
section (SCID).
16 Nine subjects were receiving psycho-
tropic drugs at baseline (low-dose atypical antipsychotics, 
n=8; antidepressant, n=1). 
The healthy control group consisted of 20 subjects who 
were age- and intelligence quotient (IQ)-matched to the 
UHR group. All were healthy adults aged 16-30 years 
with no lifetime history of any psychiatric disorder or 
treatment, and no first- to third-degree relatives with psy-
chiatric disorders. These subjects were recruited via an 
Internet advertisement or through the social networks of 
hospital staff.   
Exclusion criteria of the present study included a known 
history of psychotic illness lasting longer than 1 week, 
substance abuse or dependence, neurological disease, or 
brain injury; evidence of medical illness that could ma-
nifest psychiatric symptoms; and intellectual disability 
(IQ<70). All subjects provided written informed consent, 
and parental consent was obtained for subjects younger 
than 18 years of age. This study was conducted in ac-
cordance with the Declaration of Helsinki and approved 
by the Institutional Review Board of Seoul National Uni-
versity Hospital, Seoul, Korea.   
 
Clinical interviews and assessments 
Procedures for clinical interview and assessment are 
described in our previous report.
17 At intake, all potential 
subjects participated in an intensive clinical interview with 
two experienced psychiatrists who used the SCID
16 to 
identify past and current psychiatric illnesses. The UHR 
subjects were assessed using the CAARMS to ensure that 
the intake criteria were met. In addition, psychotic fea-
tures were evaluated using a modified 24-item version 
of the Brief Psychiatric Rating Scale (BPRS; rating items 
1-7)18 and the Positive and Negative Syndrome Scale 
(PANSS).
19 The Hamilton Rating Scale for Depression 
(HAM-D),
20 and the Hamilton Rating Scale for Anxiety 
(HAM-A)21 were also used to assess depressive and an-
xiety symptoms, respectively. The Korean version of the 
Wechsler Adult Intelligence Scale (K-WAIS) was admi-
nistered to all subjects to obtain an estimated IQ.
22 
 
Magnetic resonance spectroscopy 
All MRI and MRS experiments were performed using 
a Siemens 1.5-T system (Avanto, Germany) with a st-
andard head coil. Foam padding and a forehead-restraint 
strap were used to limit head movement during the scan. 
T1-weighted images in three orthogonal planes were used 
for positioning volumes of interest (VOIs). All subjects 
were advised of the importance of remaining motionless 
during the procedure. 
For 
1H-MRS volume location and cerebrospinal fluid 
(CSF) correction of MRS quantification, an axial three-
dimensional T1-weighted magnetization-prepared rapid 
acquisition gradient echo sequence was acquired (MPR- 
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AGE, 160 slices, TR/TE=1130/4.76 ms, inversion time= 
600 ms, matrix=256×208, FOV=173×230 mm
2, flip 
angle=15°, number of slice=160, voxel size=0.90×0.90× 
0.90 mm
3). Other T1 images were acquired for location 
information of the coronal and sagittal views (TR=1,020 
ms, TE=4.7 ms, matrix=256×240, FOV=230×230 mm
2, 
flip angle=15°). 
Spectra consisting of 16 water-unsuppressed and 128 
water-suppressed averages were acquired using a pointed 
resolved spin echo spectroscopy pulse sequence (TR= 
6,000 ms, TE=40 ms, scan time=13 min/spectrum), which 
was selected to increase the reliability of glutamate+glu-
tamine (Glx) in 1.5-T.
23 The raw data from each acquisi-
tion consisted of 2,048 points at a bandwidth of 2,500 Hz. 
The automatic shimming procedure built into the Sie-
mens system was performed for each scan. The total ex-
amination time was approximately 60 min (Figure 1). 
Three VOIs were obtained from the ACC, the left 
DLPFC, and the left thalamus (Figure 1). A 2×2×2 cm
3 
VOI in the ACC was aligned perpendicularly to the tip 
of the genu of the corpus callosum and centered at the 
interhemispheric fissure. The midpoint of the left dor-
solateral prefrontal voxel (2×1.5×2 cm
3) was positioned 
7.5 mm anterior to the genu of the corpus callosum, and 
the VOI in the left thalamus was 1.5×2×2 cm
3. Each 
VOI was carefully located on an axial slice to maximize 
the gray matter content for homogenous VOI selection 
by review of sagittal and coronal images.   
 
Postprocessing and data analysis 
Spectroscopic data (range, 4.2-1.0 ppm) were analyzed 
using LCModel (Ver 6.1-0), which has previously been 
used to identify low-concentration or overlapping meta-
bolites.
24 To ensure that high-quality spectra were ob-
tained, we verified that the full-width half-maximum for 
NAA peak was less than 0.08 ppm; if not, we reacquired 
MRS data from the region. Absolute quantifications were 
obtained through repeated trials using a calibration ph-
antom with 50 mM NAA in a 250-cm
3 spherical flask. 
 The segmentation of the MRI data into gray matter, 
white matter, and CSF components was accomplished us-
ing in-house software employing a fuzzy C-means algo-
rithm.
25 We also corrected metabolite concentrations (C0) 
for partial volume effects due to CSF by determining the 
fractional content of the CSF in the VOI (FCSF) and ap-
plying the following correction: C=C0×[1/(1-FCSF)]. 
 
Statistical analysis 
Demographic information was compared using chi-
square analyses, t-tests, and one-way analyses of variance 
(ANOVAs). Metabolite parameters were compared be-
tween groups via analysis of covariance, with age as a 
FIGURE 1. Location of volumes of in-
terest (VOIs) for magnetic resonance
spectroscopy and their sample spectra.
A: The anterior cingulate cortex. B: The
left dorsolateral prefrontal cortex. C: The
left thalamus. 
Sample spectra 
A
B
C
Chemical shift (ppm)
Chemical shift (ppm)
Chemical shift (ppm) 
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covariate in each region. Pearson’s correlation analysis 
was used to measure the association between duration of 
prodromal symptoms and brain metabolite levels. Post 
hoc comparison was done with Tukey’s test. The level of 
significance was set at p<0.05. Statistical Package for 
Social Science (SPSS)(version 14.0; SPSS Inc., Chicago, 
IL, USA) was used for all analyses. 
 
Results 
 
Demographic and clinical data 
No significant differences were observed between the 
UHR and healthy control groups in terms of age, sex ra-
tio, or IQ. Mean age was 21.80±3.11 years for the UHR 
group and 22.0±4.11 years for the healthy controls (t= 
0.695, p=0.491). The sex ratio (male/female) was 11/9 for 
the UHR group and 8/12 for healthy controls (χ2=0.902, 
p=0.342), and IQ scores were 110.25±14.39 for the UHR 
subjects and 112.05±9.74 for the healthy controls (t= 
0.463, p=0.646). Table 1 provides information on the 
demographic and clinical characteristics among UHR 
subjects with MDD, UHR subjects without MDD, and 
healthy controls. Compared to the UHR subjects without 
MDD, UHR subjects with MDD scored significantly hi-
gher on the PANSS total, BPRS, and HAM-D (Table 1). 
 
Brain metabolite data 
No significant differences were observed in the abso-
lute values of any metabolite in the ACC, left DLPFC, 
or left thalamus between the UHR group and healthy con-
trols. However when we reanalyzed brain metabolite va-
lues according to MDD comorbidity among UHR subjects, 
a significant group effect was identified for Ins concen-
tration in the left thalamus among UHR subjects with 
MDD, UHR subjects without MDD, and healthy con-
trols (F=3.825, p=0.031). Tukey’s post hoc test revealed 
a significant increase in Ins concentrations among UHR 
subjects with MDD relative to healthy controls (p=0.021; 
Figure 2) in the left thalamus. There were no significant 
differences in any other metabolite level in any brain re-
gion among UHR subjects with MDD, UHR subjects 
without MDD, or healthy controls (Table 2). 
To control the effect of medications in the UHR group, 
we performed additional analysis in drug-naïve UHR 
subjects (n=11). This analysis revealed that Ins concen-
trations increased significantly in the left thalamus of 
drug-naïve UHR subjects compared to healthy controls 
(Ins: F=5.032, p=0.033). Upon further analysis, however, 
a significant comorbidity effect was observed for Ins con-
centrations in the left thalamus among drug-naïve UHR 
subjects with MDD, those without MDD, and healthy 
controls (Ins: F=3.656, p=0.039), although the sample 
TABLE 1. Demographic and clinical characteristics in ultra-high risk subjects and healthy controls
Analysis 
 
UHR with MDD   
(N=11) 
UHR without MDD 
(N=9) 
Healthy control   
(N=20)   p 
Demographic variables 
Age (years)  021.55±03.05  022.11±03.33  022.60±4.11 F=0.294  p=0.747 
Sex (male/female) 8/3  3/6  8/12  χ2=3.983 p=0.137 
IQ 112.09±14.75 108.00±14.47 112.05±9.74 F=0.377  p=0.688 
Clinical variables 
Duration of prodromal symptoms (years)  002.88±02.10  002.38±01.93   t=-0.553  p=0.587 
PANSS (total)  060.00±05.98  050.00±09.85   t=-2.803  p=0.012* 
BPRS  046.55±03.67  038.00±09.71   t=-2.706  p=0.014* 
HAM-D  017.18±04.24  011.56±07.37   t=-2.144  p=0.046* 
HAM-A  014.27±05.62  010.56±08.55   t=-1.169  p=0.258 
CAARMS (total)  040.27±10.39  032.33±15.38   t=-1.375  p=0.186 
Data are given as mean±SD. *p<0.05. UHR: ultra-high risk, MDD: major depressive disorder, IQ: intelligence quotient, PANSS: Positive and 
Negative Syndrome Scale, BPRS: Brief Psychiatric Rating Scale, HAM-D: Hamilton Depression Rating Scale, HAM-A: Hamilton Anxiety 
Rating Scale, CAARMS: Comprehensive Assessment of At-Risk Mental States   
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FIGURE 2. Absolute concentrations of myo-inositol in the left
thalamus among the UHR group with MDD, those without MDD,
and control group. *p=0.021. UHR: ultra-high risk, MDD: major de-
pressive disorder.    
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size was small. Tukey’s post hoc test revealed that drug-
naïve UHR subjects with MDD (n=6) showed increased 
Ins levels in the left thalamus compared to healthy con-
trols (Ins: 3.55±0.75 versus 2.58±0.71, p=0.019). 
Using Pearson’s correlation analysis, we found a sig-
nificant positive correlation between Cho concentrations 
in the left thalamus and the duration of prodromal symp-
toms in the UHR group (r=0.495, p=0.027). In addition, 
we observed a trend toward positive correlation between 
thalamic Ins levels and the duration of prodromal symp-
toms in the UHR group (r=0.412, p=0.071). However, 
when the analysis was limited to UHR subjects with MDD, 
no significant correlation was observed between brain 
metabolite levels and clinical data. 
 
Discussion 
 
In the present study, no differences in brain metabo-
lite levels within the ACC, left DLPFC, or left thalamus 
were observed between UHR subjects and healthy con-
trols. However, a significant increase in Ins levels was 
observed in the left thalamus in UHR subjects with co-
morbid MDD compared to healthy controls. To our know-
ledge, this is the first report demonstrating alterations in 
brain metabolite levels in UHR subjects with comorbid 
MDD using 
1H-MRS. 
The level of brain metabolites obtained by MRS pro-
vides us much valuable information with the function of 
the brain in vivo, which is one of major strengths that 
MRS studies have. Although there are more than 6 brain 
metabolites that can be assessed by MRS, we investi-
gated 6 molecules including NAA, Cho, Cr, Ins, and Glx, 
which have been examined in previous MRS studies of 
subjects at UHR or high genetic risk of psychosis and 
patients with schizophrenia.
5,13,26-28 NAA levels may re-
present sensitive means of monitoring neuronal cellular 
function.
29,30 Cho levels can be used as an indicator of 
membrane turnover. Cr levels represent cellular energy 
metabolism. Ins is found primarily in glial cells and can 
be used as a marker of glial cell function.
31 Increased Glx 
concentrations are reported to be related with excitoto-
xicitiy.
27 
Contrary to previous MRS studies, 
1H-MRS did not 
reveal any significant alteration in brain metabolite le-
vels in the UHR group. The results of two previous studies 
investigating brain metabolites in UHR subjects were 
inconsistent in this regard. For example, Jessen et al.
5 
reported that NAA/Cr ratios decreased in the frontal 
lobe, whereas Wood et al.
4 reported increased NAA/Cr 
ratios in the frontal lobe. In addition, these studies did not 
account for between-group age differences, medications, 
or comorbidity. In this study, we addressed the potential 
confounding effects of medication by performing an ad-
ditional analysis in drug-naïve UHR subjects (n=11), 
which revealed a significant increase in Ins concentra-
tions in the left thalamus compared to healthy controls. 
However, these differences were influenced by the pre-
sence of comorbid MDD; only drug-naïve UHR subjects 
TABLE 2. Absolute concentrations (mM) of brain metabolites for ultra-high risk subjects and healthy controls 
  UHR with MDD (N=11)  UHR without MDD (N=9) Healthy control (N=20) F  p 
Anterior cingulate cortex 
NAA  09.91±0.65 10.24±0.80  09.96±0.76 0.714  0.496 
Cr 10.38±1.11 10.68±1.36 10.54±0.85 0.155  0.857 
Cho  01.83±0.15  01.86±0.26  01.81±0.23 0.131  0.878 
Ins  04.99±0.73  05.14±0.59  05.25±0.66 0.521  0.598 
Glx 11.41±2.58 11.73±2.20 11.92±1.93 0.090  0.914 
Dorsolateral prefrontal cortex 
NAA  09.39±2.10  09.29±1.36  08.72±1.02 1.090  0.347 
Cr  06.86±1.83  06.67±0.88  06.49±0.98 0.420  0.660 
Cho  01.36±0.51  01.39±0.28  01.28±0.27 0.480  0.623 
Ins  03.89±1.25  03.54±0.78  03.33±0.76 1.653  0.206 
Glx  05.97±3.77  06.92±3.45  07.62±2.66 0.985  0.386 
Thalamus 
NAA  08.50±1.01  08.50±1.27  08.22±0.83 0.346  0.710 
Cr  06.12±0.64  05.74±0.76  05.83±0.63 0.977  0.386 
Cho  01.59±0.15  01.44±0.23  01.49±0.24 1.152  0.327 
Ins  03.33±0.63  02.70±0.79  02.58±0.71 3.825  0.031* 
Glx  05.73±0.88  05.19±1.00  05.63±1.74 0.460  0.635 
Data are given as mean±SD. *p<0.05. UHR: ultra-high risk, MDD: major depressive disorder, NAA: N-acetylaspartate, Cr: creatine, Cho:
choline, Ins: myo-inositol, Glx: glutamate+glutamine 
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with MDD showed higher Ins than healthy controls. 
Depression is one of the most frequent prodromal symp-
toms and the occurrence of depressive symptoms ap-
pears to have prognostic implications for the type and 
severity of symptoms in first-episode psychosis.
7 More-
over, Yung et al.
8 reported that severe depression was a 
predictor of psychosis. Of particular interest, we observ-
ed a significant increase in Ins concentrations in the left 
thalamus in UHR subjects with MDD compared to heal-
thy controls. The thalamus is an important component of 
the limbic system that plays a role in the processing of 
emotion, and thalamic dysfunction is involved in the pa-
thophysiology of MDD.
32-35 Structurally, Young et al.
33 
reported that the number of neurons in the thalamus in-
creased in patients with MDD compared to healthy con-
trols. Functionally, thalamic metabolism
36 and resting-
state thalamic functional connectivity
34 increased signi-
ficantly in patients with MDD. To date, however, only 
few MRS studies have examined the role of the thalamus 
in MDD,
37,38 instead, the majority of studies focused on 
the DLPFC, ACC or basal ganglia. In the present study, 
increased thalamic Ins concentrations suggest that the 
disruption of secondary messenger systems may occur 
in UHR subjects with MDD. Ins is an important consti-
tuent of the phosphatidylinositol (PI) secondary messen-
ger system. Given that the human brain obtains most of 
its Ins supply from resynthesis through the PI cycle and 
that diverse receptors are coupled to the PI cycle,
39 al-
terations in the Ins level may influence specific neuronal 
ganglia. In addition, dysfunction in the coupling meta-
bolism of the receptor-secondary messenger system com-
plex may provide an important biological substrate to 
UHR subjects experiencing prodromal depressive symp-
toms. Ins may also be a useful glial marker
40 and stored 
in glial cells before its consumption in the PI cycle of 
neurons.
41 Therefore, alterations in the Ins level may re-
present astroglial dysfunction that can be one of the pos-
sible biological mechanism of prodromal depressive symp-
toms in UHR subjects, although this hypothesis still need 
to be more investigated to be verified. 
There were significant differences in PANSS total and 
BPRS scores between UHR subjects with MDD and those 
without MDD. To exclude the possible effect of PANSS 
total score difference on increased Ins concentrations in 
the UHR group with MDD, after stratifying the UHR 
group according to mean PANSS total score, no signi-
ficant difference in Ins levels in the left thalamus was 
observed between UHR subjects with high PANSS total 
scores (PANSS score ≥56, n=11), UHR subjects with 
low scores, and healthy controls (F=1.847, p=0.172). Th-
erefore, comorbid MDD may account for the observed 
increase in Ins concentrations in UHR subjects. 
A trend toward a positive correlation between thala-
mic Ins levels and the duration of prodromal symptoms, 
and a significant positive correlation between Cho con-
centrations in the thalamus and the duration of prodro-
mal symptoms were observed in the UHR group. As Cho 
is a primary constituent of cell membrane phospholipids, 
increased Cho levels can be interpreted as increased 
membrane turnover. Théberge et al.
13 found a positive 
correlation between Cho levels in the left ACC and left 
thalamus and the duration of untreated psychosis, sup-
porting the concept that Cho functions as a disease ac-
tivity marker. Similarly, our results may indicate that dis-
ease-related processes, such as increased membrane turn-
over, may be occurring in UHR subjects, although we did 
not observe a significant difference in Cho concentrat-
ions between the UHR group and the healthy controls. 
Our study has some important limitations. First, we 
were unable to include patients with schizophrenia. But 
although comparing brain metabolite values between UHR 
subjects and patients with schizophrenia was impossible, 
alterations in Ins levels according to comorbid MDD 
among UHR subjects would be convincing of elucidat-
ing the effect of depressive symptoms on brain of indi-
viduals at UHR for psychosis. Second, our sample size 
was small. Additional analysis to control the effect of 
comorbid MDD and medication might have possibilities 
to lower the statistical power. However, the other MRS 
studies about the UHR subjects and first episode schizo-
phrenia also had a limitation with the number of sub-
jects due to the rarity of the subject group.
4,42 Therefore, 
a longitudinal follow-up investigation with a larger sam-
ple size is required in the future. In addition, comorbid 
anxiety disorder and bipolar disorder were not excluded 
in this study. Alteration of brain metabolites such as lac-
tate, GABA, Ins is reported in subjects with anxiety dis-
order and bipolar disorder.
40,43 
In summary, our results demonstrate that increased 
thalamic Ins concentrations are associated with prodro-
mal depressive symptoms in UHR subjects. More MRS 
studies in UHR subjects with longitudinal design will be 
needed to discover a biomarker of vulnerability to psy-
chosis. 
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